BioSpace1d
EU Rejects Lilly’s Alzheimer’s Drug Kisunla, Following Same Path as Rival Leqembi
The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...
EU regulators block new Alzheimer’s drug citing potentially fatal side effects
The company behind the drug donanemab said it will ask regulators to reconsider the decision. View on euronews ...
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update
Eli Lilly, which is seeking European approval of Kisunla for the treatment of early symptomatic Alzheimer's, said it will seek re-examination by CHMP. The Indianapolis drugmaker said it remains ...
From cancer vaccines to COPD treatments, these 10 companies are developing innovative medicines
Eli Lilly, Adaptimmune, Aurion Biotech, and ImmunityBio had breakthrough medicines and therapies debut in the past year.
STAT1d
Eli Lilly’s Alzheimer’s drug gets thumbs-down from European regulators
Eli Lilly's Kisunla was approved in the U.S. for Alzheimer's last year, but now advisers to the European Medicines Agency say ...
Medical Marketing & Media2d
DTC platform LillyDirect expands to provide access for Alzheimer’s care
Eli Lilly is expanding care offerings on its direct-to-consumer (DTC) platform LillyDirect, now offering connections to ...
Morningstar2d
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug — Update
Eli Lilly, which is seeking European approval of ... The U.S. Food and Drug Administration last year approved Kisunla, an antibody drug given as a monthly intravenous infusion that studies show ...
Morningstar2d
CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug
Eli Lilly, which is seeking European approval of ... The U.S. Food and Drug Administration last year approved Kisunla, an antibody drug given as a monthly intravenous infusion that studies show ...